Critical Analysis: Halozyme Therapeutics (NASDAQ:HALO) and Athira Pharma (NASDAQ:ATHA)

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) and Athira Pharma (NASDAQ:ATHAGet Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Risk and Volatility

Halozyme Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.83, suggesting that its stock price is 183% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Halozyme Therapeutics and Athira Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics 0 1 5 0 2.83
Athira Pharma 0 0 1 0 3.00

Halozyme Therapeutics presently has a consensus price target of $53.14, indicating a potential upside of 21.00%. Athira Pharma has a consensus price target of $19.00, indicating a potential upside of 642.19%. Given Athira Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Halozyme Therapeutics.

Valuation & Earnings

This table compares Halozyme Therapeutics and Athira Pharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Halozyme Therapeutics $862.99 million 6.48 $281.59 million $2.42 18.15
Athira Pharma N/A N/A -$117.67 million ($3.05) -0.84

Halozyme Therapeutics has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 2.7% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 19.8% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares Halozyme Therapeutics and Athira Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halozyme Therapeutics 36.94% 225.71% 20.52%
Athira Pharma N/A -80.59% -67.70%


Halozyme Therapeutics beats Athira Pharma on 9 of the 13 factors compared between the two stocks.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

About Athira Pharma

(Get Free Report)

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with's FREE daily email newsletter.